• Medpace Holdings is trading at $635.00, down 5.11% in after-hours trading.
  • The decline follows the company's Q3 2026 earnings report, where full-year revenue guidance fell short of analyst expectations, despite adjusted earnings and revenue for the quarter exceeding estimates.
  • The company also authorized a $1 billion share repurchase program.